Mini-dose Dexmedetomidine-Esketamine Infusion and Perioperative Sleep Quality
Status:
Recruiting
Trial end date:
2027-12-01
Target enrollment:
Participant gender:
Summary
Sleep disturbances are prevalent in older patients with osteoarthrosis or fracture who are
scheduled for knee or hip replacement surgery. The occurrence of sleep disturbances is
associated with worse outcomes including increased risk of delirium and cardiac events, and
worsened functional recovery. Dexmedetomidine is a highly selective α2-adrenergic agonist
with sedative, anxiolytic, and analgesic properties. It exerts sedative effects via
activating the endogenous sleep pathways and produces a state like non-rapid eye movement
sleep, which is different from opioid- and benzodiazepine-induced sedation. Esketamine is a
N-methyl-D-aspartic acid receptor antagonist and has been used as an anesthetic and
analgesic. Recent studies showed that low-dose esketamine has anti-depressive and
sleep-promoting effects. The investigators suppose that mini-dose dexmedetomidine-esketamine
combined infusion at night can improve perioperative sleep quality in patients scheduled for
knee or hip replacement surgery.